Transgene’s Board of Directors Proposes the Appointment of Carol Stuckley, MBA, as New Independent Director
STRASBOURG, France–(BUSINESS WIRE)–#HBV–Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced that the Board of Directors has proposed Ms. Carol Stuckley, MBA, as an independent Director of the Company. This appointment reflects the continued evolution of Transgene’s corporate governance, which takes into account … [Read more…]
